WO2011103135 THE USE OF MIR-30E TO TREAT VASCULAR LESIONS

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

Publication Number WO/2011/103135

Publication Date 25.08.2011

International Application No. PCT/US2011/025005

International Filing Date 16.02.2011

IPC

CPC

View more classifications

View less classifications

Applicants

UNIVERSITY OF MIAMI [US]/[US] (AllExceptUS)
SHEHADEH, Lina [US]/[US] (UsOnly)

Inventors

SHEHADEH, Lina

Agents

ZACHARIADES, Nicholas, A.

Priority Data

61/304,858

16.02.2010

Publication Language English (en)

Filing Language English (EN)

Designated States

View all

Title

(EN) THE USE OF MIR-30E TO TREAT VASCULAR LESIONS

(FR) UTILISATION DE MIR-30E POUR TRAITER LES LÉSIONS VASCULAIRES

Abstract

(EN) MicroRNA molecules are directed to the treatment of diseases associated with plaque formation, cardiovascular diseases, inflammation, stroke, and disorders associated with aging.

(FR) Les molécules de micro-ARN selon l'invention permettent de traiter les maladies associées à la formation de plaques, les maladies cardiovasculaires, l'inflammation, l'attaque, et les troubles associés au vieillissement.

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5	Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07	Animal cells or tissues

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5	Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10	Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
12	Fused cells, e.g. hybridomas
16	Animal cells

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5	Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07	Animal cells or tissues

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5	Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10	Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
12	Fused cells, e.g. hybridomas
16	Animal cells

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13	Drugs for disorders of the urinary system

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. WO2011103135 - THE USE OF MIR-30E TO TREAT VASCULAR LESIONS

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09	Recombinant DNA-technology
11	DNA or RNA fragments; Modified forms thereof
113	Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing